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INTRODUCTION
Imagine: a woman named Anne has been suffering from Crohn’s
disease for several years.1 Her symptoms, including extreme abdominal
pain and burning ulcers, make daily life difficult.2 She tries several types
of medication without success until her doctor recommends3 that she use
medical marijuana—a practice the Louisiana Legislature recently made
legal.4 Anne finds that the use of medical marijuana significantly relieves
her symptoms.
Anne goes to work and informs the Human Resources department that
she has begun to use medical marijuana per her doctor’s recommendation.
She assures the Human Resources representative that she will not use
medical marijuana on company property or while on the job and that she
will not be impaired during the workday. The Human Resources
representative tells Anne that since state law sanctions her marijuana use she
will not face any repercussions.5 Within a few days, however, Anne’s
employer forces her to take a drug test pursuant to the company’s random
drug testing policy. Upon testing positive for marijuana use, Anne is
terminated.6
Copyright 2019, by CATHERINE BRILEY.
1. Anne is a fictional person introduced to relay a real shortcoming in
Louisiana law.
2. See generally Crohn’s Disease, MAYO CLINIC (Aug. 7, 2017), https://
www.mayoclinic.org/diseases-conditions/crohns-disease/symptoms-causes/syc-20
353304 [https://perma.cc/YA2M-36AZ].
3. See LA. REV. STAT. § 40:1046 (2018). Louisiana’s medical marijuana
statutes use the term “recommend” rather than “prescribe” in order to protect
doctors from violating the Controlled Substances Act, which forbids medical
professionals from prescribing marijuana. 21 U.S.C. § 812(c)(10) (2012); see also
James Gill, Lawmakers Play Word Games on Medical Marijuana, ADVOCATE
(June 8, 2016, 5:13 PM), https://www.theadvocate.com/new_orleans/opinion
/james_gill/article_3db8e178-7713-53ee-9453-dc15762924fc.html [https://perma
.cc/CF85-AXCC].
4. LA. REV. STAT. § 40:1046 (creating a method by which doctors are able
to recommend medical marijuana to patients suffering from any of the debilitating
illnesses specifically listed in the statute).
5. See id. § 40:966(I) (providing exemptions for arrest and prosecution to
persons lawfully in possession of medical marijuana); see also id. §
40:1046A(2)(a) (providing a plan for the production, cultivation, and distribution
of medical marijuana and listing Crohn’s disease as a debilitating medical
condition which medical marijuana can be recommended to treat).
6. See id. §§ 40:1001–05 (allowing employers to conduct random drug
testing of employees as a condition of their employment).
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Following her termination, Anne discusses possible legal recourse
with her lawyer for discrimination under the Americans with Disabilities
Act of 1990 (“ADA”).7 The attorney informs Anne that the ADA provides
no remedy because it specifically exempts individuals “currently engaging
in the illegal use of drugs.”8 The use of marijuana is illegal under the
federal Controlled Substances Act (“CSA”) even though Louisiana law
allows for its medical use.9 Louisiana law allows a doctor to recommend
medical marijuana to a patient for certain severe, debilitating medical
conditions10 and allows a patient to use medical marijuana without fear of
criminal prosecution,11 but the law does nothing to protect workers from
discrimination based on their use of a state-sanctioned medicine.12 Anne’s
attorney tells her the harsh reality she faces: the ADA does not protect her
from discrimination based on her use of marijuana, and Louisiana law
offers no solution either. Upon discovery of her lack of legal recourse,
Anne is faced with her reality: no job and slim prospects for future
employment unless she stops using medical marijuana to manage her
painful condition.
Although Anne’s situation is presently hypothetical, various Louisiana
citizens will find themselves in her shoes if the legislature does not fill the
existing gaps in Louisiana’s medical marijuana statutes.13 Louisiana is
currently laying the groundwork for legal production and distribution of
marijuana, and the producers that state legislators selected expect eligible
patients to have access to the medicine in early 2019.14 The lack of

7. 42 U.S.C. §§ 12111–17.
8. Id. § 12114.
9. Id.; see also LA. REV. STAT. § 40:966(I) (providing exemptions for arrest
and prosecution to persons lawfully in possession of medical marijuana); see also
21 U.S.C. § 812(c)(10) (designating the statutorily defined “marihuana” as a
Schedule I controlled substance).
10. LA REV. STAT. § 40:1046 (listing “cancer, positive status for human
immunodeficiency virus, acquired immune deficiency syndrome, cachexia or
wasting syndrome, seizure disorders, epilepsy, spasticity, Crohn’s disease,
muscular dystrophy, or multiple sclerosis” as the qualifying debilitating medical
conditions medical marijuana can be recommended to treat).
11. See id. § 40:966 (providing exemptions for arrest and prosecution to
persons lawfully possessing medical marijuana).
12. See id.; see also id. § 40:1046 (lacking any protection against employment
discrimination on the basis of medical marijuana use).
13. Id.
14. See Stephanie Riegel, Medical marijuana behind schedule, again, but
program making progress, GREATER BATON ROUGE BUS. REP. (Aug. 29, 2018),
https://www.businessreport.com/article/medical-marijuana-behind-schedule-pro
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employment protections is a gap in the statutory scheme that lawmakers
must correct to ensure that no Louisiana citizen has to face an impossible
choice between health and employment.
Marijuana is a drug with a reputation because of its long illegality and
psychoactive nature, and some argue that lawmakers should not grant legal
protections to individuals who use the substance.15 The decriminalization
of medical marijuana in Louisiana faced criticism, with skeptics claiming
that de facto legalization of marijuana in any context encourages substance
abuse.16 Others object to decriminalization because of the lack of research
on marijuana’s efficacy as a therapeutic treatment and accuse the
Louisiana Legislature of moving too fast when it decriminalized use of the
plant for medical purposes.17 Substantial research has demonstrated,
however, that marijuana can improve the symptoms of individuals
suffering from illnesses such as cancer and Crohn’s disease.18 The research
gram-making-progress [https://perma.cc/HFZ2-F6D3] (discussing delays in the
production and distribution of the first crop of medical marijuana and its expected
availability in early 2019).
15. See The Controlled Substances Act of 1970, 21 U.S.C. § 812 (2012); see
also Robert L. DuPont, Marijuana Has Proven to Be a Gateway Drug, N.Y. TIMES
(Apr. 26, 2016, 3:22 AM), https://www.nytimes.com/roomfordebate/2016/04/26/ismarijuana-a-gateway-drug/marijuana-has-proven-to-be-a-gateway-drug [https://per
ma.cc/8L75-ZE3U].
16. See, e.g., Dean Robinson & A. Kennison Roy, ‘Medical’ marijuana bill
will do more harm than good, professionals argue in guest column, ADVOCATE
(May 10, 2016, 5:20 PM), https://www.theadvocate.com/baton_rouge/opinion
/our_views/article_53552655-0124-5afe-8700-c0e1a23ab3ce.html [https://perma
.cc/A3QD-ZNNT]; Ken Roy, Letter to the Editor, Jindal should veto medical
marijuana bill, ADVOCATE (June 16, 2016, 2:02 PM), https://www.theadvocate
.com/baton_rouge/opinion/letters/article_054147fd-cb46-53f9-a199-2fc0cb1c11ef
.html [https://perma.cc/CV2E-MQAM]; Mike Stone & Michael A. Ranatza,
Opinion, Louisiana Sheriffs’ Association leaders: Balance needed on medical
marijuana, ADVOCATE (May 8, 2016, 11:36 AM), https://www.theadvocate.com
/baton_rouge/opinion/our_views/article_3f4a5486-9285-5f4b-9095-28f2f25d617
3.html [https://perma.cc/8VMP-CLHB].
17. See, e.g., Robinson & Roy, supra note 16; Roy, supra note 16; Stone &
Ranatza, supra note 16.
18. See Mary E. Lynch & Fiona Campbell, Cannabinoids for Treatment of
Chronic Non-Cancer Pain; A Systematic Review of Randomized Trials, 72 BRIT.
J. CLINICAL PHARMACOLOGY 735, 742 (2011) (finding that marijuana is a
“modestly effective and safe treatment option for chronic non-cancer
(predominantly neuropathic) pain”); see also Brenda E. Porter & Catherine
Jacobson, Report of a Parent Survey of Cannabidiol-Enriched Cannabis Use in
Pediatric Treatment-Resistant Epilepsy, 29 EPILEPSY & BEHAV. 574, 575 (2013)
(finding that parents using marijuana to treat children's epilepsy report a “high
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demonstrating medical marijuana’s benefits, as well as Louisiana citizens’
personal testimony that medical marijuana alleviated symptoms, led
Louisiana to decriminalize the substance for medical use.19 If Louisiana is
willing to allow the use of marijuana therapeutically, it should not force
citizens to choose between health and the ability to earn a living.
This Comment recommends that the Louisiana Legislature fill the current
gaps in medical marijuana legislation before marijuana is recommended for
medical use in this state.20 The solution lies in amending Louisiana Revised
Statutes § 40:1046 to include anti-discrimination protection from adverse
employment action, as Connecticut, Arizona, and several other states have
done in connection with the legalization of medical marijuana.21 The new antidiscrimination provision should create a private cause of action for employees
to sue their employers in the event that the employees are wrongfully
terminated for their legal use of medical marijuana.22
Part I of this Comment discusses the current status of marijuana
legislation in the United States at both the federal and state levels. It
provides a background on the tension between the federal CSA and state
decriminalization efforts. Part II focuses on state medical marijuana
statutes in the context of employment law, including significant court
decisions either upholding or dismissing statutory protections from
wrongful termination for marijuana use. Part III examines the current state
of Louisiana’s medical marijuana statutes and analyzes their inability to
rate of success in reducing seizure frequency with this treatment”); see also Jody
Corey-Bloom et al., Smoked Cannabis for Spasticity in Multiple Sclerosis: A
Randomized, Placebo-Controlled Trial, 184 CANADIAN MED. ASS’N J. 1143,
1145 (2012) (administering marijuana to patients with multiple sclerosis and
spasticity resulted in a “clinically meaningful” reduction in pain).
19. See The Advertiser, Editorial, Medical marijuana bill deserves support,
ADVERTISER (May 26, 2015, 2:18 PM), http://www.theadvertiser.com/story/opin
ion/2015/05/26/medical-marijuana-bill-deserves-support/27971151/
[https://per
ma.cc/AYQ9-H77M]; Ken Stickney, How Louisiana’s medical marijuana bill has
evolved, ADVERTISER (May 9, 2015, 11:06 PM); Kris Wartelle, Mother’s dying wish
to legalize medical marijuana granted, ADVERTISER (June 11, 2015, 3:30 PM)
http://www.theadvertiser.com/story/news/2015/06/11/womans-dying-wish-legal
ize-medical-marijuana-granted/71074362/ [https://perma.cc/A597-85TL].
20. See Riegel, supra note 14.
21. See CONN. GEN. STAT. § 21a-408p(b) (2018); ARIZ. REV. STAT. § 362813 (2018); DEL. CODE ANN. tit. 16, § 4905A (2018); 410 ILL. COMP. STAT.
130/40 (2018); ME. REV. STAT. tit. 22, § 2423–E (2018); NEV. REV. STAT. §
453A.800 (2018); N.Y. PUB. HEALTH LAW § 3369 (2018); MINN. STAT. § 152.32;
R.I. GEN. LAWS § 21–28.6–4 (2018).
22. See generally Noffsinger v. SSC Niantic Operating Co. LLC, 273 F.
Supp. 2d 326 (D. Conn. 2017).
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protect Louisiana employees who use medical marijuana pursuant to a
doctor’s recommendation. Part IV proposes solutions, the best solution
being a statutory provision creating a cause of action for employees to sue
for wrongful termination under the statutes decriminalizing medical
marijuana. This Comment concludes by emphasizing the need for
Louisiana lawmakers to show foresight by protecting citizens whose statesanctioned medical marijuana use may threaten their livelihoods.
I. REGULATION OF MARIJUANA POSSESSION AND USE AT THE FEDERAL
AND STATE LEVELS
Marijuana and all of its components and derivatives have been illegal
under federal law since 1970.23 Thirty-three states, however, have
decriminalized the possession and use of marijuana for medical
purposes.24 The wholesale forbiddance of marijuana under federal law and
the contrasting state law legalization of marijuana for particular purposes,
namely medicinal use, have led to tension in the law. Questions regarding
preemption and principles of federalism are central to marijuana
legislation, as the answers to those questions determine whether states
have the power to decriminalize medical marijuana or offer employment
protection to marijuana users.25
A. Federal Prohibition of Marijuana
The CSA categorizes controlled substances into one of five Schedules
based on the substance’s potential for abuse and potential medical uses.26
The most severe classification under the CSA is Schedule I, since
substances categorized as Schedule I drugs are those that Congress finds
have the highest risk of abuse and no recognized medical use.27 In 1970,
Congress designated marijuana and all of its components as Schedule I

23. See 21 U.S.C. § 812(c)(10) (2012).
24. State Medical Marijuana Laws, NAT’L CONF. ST. LEGISLATURES (Nov.
8, 2018), http://www.ncsl.org/research/health/state-medical-marijuana-laws.aspx
[https://perma.cc/X6HG-PUM6].
25. See Lea Brilmayer, A General Theory of Preemption: With Comments on
Statement Decriminalization of Marijuana, 58 B.C. L. REV. 895 (2017); see also
Erwin Chemerinsky et al., Cooperative Federalism and Marijuana Regulation,
62 UCLA L. REV. 74 (2015).
26. 21 U.S.C. § 812.
27. Id. § 812(b)(1).
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controlled substances under the CSA.28 This classification placed
marijuana in the same category as heroin, cocaine, and lysergic acid
diethylamide.29 Marijuana’s classification as a Schedule I substance makes
its cultivation, possession, and use for any purpose illegal under federal
law.30 The penalties for violating the CSA’s prohibition of marijuana are
significant, and the legality of the marijuana cultivation or possession
under state law has no bearing on the federal law’s treatment of violators.31
First-time possessors of marijuana face up to a year in prison and a $1,000
fine, but even a small producer of marijuana plants faces up to five years
in prison and a fine of up to $250,000.32 The CSA’s plain language would
punish state-sanctioned users and producers of medical marijuana just as
harshly as users and drug dealers whose activities are entirely illicit.33
Contemporaries have questioned marijuana’s classification as a
Schedule I substance since the passage of the CSA because of the drug’s
potential medical benefits.34 Within two years of the CSA’s passage, a
commission Congress created to research marijuana recommended the
rescheduling and decriminalization of marijuana for medical research
purposes.35 Later clinical studies in which the Food and Drug
Administration approved of marijuana have proven what the commission
found to be true at the outset of the CSA’s existence: marijuana has
possible medical value and therefore should not be a Schedule I substance
under the CSA.36 Studies demonstrating potential medical purposes for
marijuana have had no effect on federal law.37 The federal government has
not entirely ignored such medical studies, however, as the majority of state

28. See id. § 802(16) (defining marijuana as “all parts of the plant Cannabis
sativa L.”); see also id. § 812(c)(10) (designating the statutorily defined
“marijuana” as a Schedule I controlled substance).
29. See id. § 812.
30. Id. § 844(a).
31. See id. § 841 (giving the penalty guidelines for various types of CSA
violations involving marijuana).
32. See id. (giving the penalties for a first-time possessor and a cultivator with
less than 50 plants).
33. See id. (setting penalty guidelines with no distinctions for violators acting
in accord with state law).
34. NAT’L COMM’N ON MARIJUANA AND DRUG ABUSE, MARIHUANA: A
SIGNAL OF MISUNDERSTANDING (1972).
35. Id.
36. See supra note 18.
37. 21 U.S.C. § 844(a).
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governments have taken notice and started to decriminalize the use of
medical marijuana.38
B. State Decriminalization of Marijuana for Medical Purposes
Although federal law recognizes no medical use for marijuana, the
majority of states have created statutory schemes allowing access to
marijuana or some of its derivatives—like cannabinoids and cannabis
oil—for medical purposes.39 Despite lingering concerns about the
potentially harmful effects of marijuana, state legislatures justify medical
marijuana laws based on findings that patients can use medical marijuana
to provide relief for conditions such as cachexia, cancer, glaucoma, AIDS,
nausea, post-traumatic stress syndrome, severe pain, seizures, persistent
muscle spasms, and multiple sclerosis.40 Marijuana is generally used to
relieve pain, combat malnutrition and loss of appetite, and reduce
muscular spasms or seizures.41
All states with medical marijuana programs protect residents who
qualify for treatment with medical marijuana from state criminal
prosecution.42 Some states, such as Massachusetts and Michigan, grant
even broader protections to protect medical marijuana patients from being
denied any right or privilege based on their use of medical marijuana. 43

38. See State Medical Marijuana Laws, supra note 24 (listing 33 states which
allow for public medical marijuana programs and 18 states which allow use of
low THC, high cannabidiol products for medical reasons).
39. Id.
40. See Oregon Medical Marijuana Program Statistics, OR. HEALTH AUTH.,
http://www.oregon.gov/oha/PH/DISEASESCONDITIONS/CHRONICDISEAS
E/MEDICALMARIJUANAPROGRAM/Documents/OMMP%20Statistic%20Sn
apshot%20-%2004-2017.pdf [https://perma.cc/ED87-LZVR] (last updated Apr.
2017) (listing above diseases as covered under Oregon state medical marijuana law);
see also LA. REV. STAT. § 40:1046 (2018) (listing above diseases as debilitating
medical conditions eligible for treatment with recommended medical marijuana).
41. See supra note 18.
42. MARIJUANA POLICY PROJECT, STATE-BY-STATE MEDICAL MARIJUANA
LAWS (2015), https://www.scribd.com/document/264980279/State-by-StateLaws-Report-2015 [https://perma.cc/ATF4-2BCV].
43. MASS. GEN. LAWS ch. 94C app., § 1-4 (West 2006 & Supp. 2014); M ICH.
COMP. LAWS ANN. § 333.26424 (West 2001 & Supp. 2017); see also ALASKA
STAT. § 17.37.030 (2012); CAL. HEALTH & SAFETY CODE § 11362.5(b)(1)(B)
(West 2007 & Supp. 2016); MONT. CODE ANN. § 50-46-319 (2016); N.J. STAT.
ANN. § 24:61-2 (West 2007 & Supp. 2017); N.M. STAT. ANN. § 26-2B-4 (2007
& Supp. 2017); OR. REV. STAT. § 475.300 (2016); R.I. GEN. LAWS § 21-28.6-4
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Nine states explicitly protect medical marijuana users from employment
discrimination based on a positive drug test.44 A stark contrast exists
between the planes of federal and state law on this issue, however, because
although medical marijuana use is legal under the laws of the individual
states that have provided for such use, it remains illegal under the CSA.45
C. Disparity in Federal and State Law Governing Marijuana Use
The federal government has recognized the disparity between state
law’s allowance of medical marijuana use and federal law’s wholesale ban
on marijuana, and it has taken steps to address the differences. Both the
executive and legislative branches have attempted to bridge the divide
between the CSA and state decriminalization efforts. The goal of these
steps is to permit the states the ability to regulate marijuana but maintain
that the federal government, through the CSA, has the final say on the
legality of any marijuana use. In 2017, the change in administration
upended the status quo, bringing into question whether the federal
government’s next move will be to enforce the CSA in spite of state
decriminalization efforts.46
1. Executive Agency Actions
During the Obama Administration and up until January 2018,
executive agencies dealt with the tension between state and federal law by
directing federal prosecutors to follow a policy of non-interference with
state programs that allowed for the regulated use of marijuana.47 This
(2002 & Supp. 2013); WASH. REV. CODE § 69.5 1A.040 (West 2007 & Supp.
2017); see also MARIJUANA POLICY PROJECT, supra note 42.
44. See supra note 21.
45. See 21 U.S.C. § 812 (2012).
46. In 2017, Donald J. Trump was inaugurated as President of the United States
and began shifting the policies of the Executive Branch to the right through his
appointments. The most significant administrative change was the appointment of
Jefferson Beauregard Sessions, a stringent opponent of marijuana legalization, as
Attorney General. See Memorandum from Jefferson B. Sessions, III, U.S. Attorney
General, to All U.S. Attorneys (Jan. 4, 2018), https://www.justice.gov/opa/pressrelease/file/1022196/download
[https://perma.cc/6LYE-N8EV]
[hereinafter
“Sessions Memo”] (rescinding previous nationwide guidance specific to marijuana
enforcement, including the Ogden and Cole Memoranda).
47. See Memorandum from David W. Ogden, Deputy Attorney General, to
Selected U.S. Attorneys (Oct. 19, 2009), https://www.justice.gov/sites/default
/files/opa/legacy/2009/10/19/medical-marijuana.pdf [https://perma.cc/R4GM-DD
RM] [hereinafter “Ogden Memo”] (establishing guidelines on investigations and
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policy was set forth in guidance documents and generally recommended
that federal prosecutors not disrupt state medical marijuana regulation by
single-mindedly enforcing CSA prohibitions.48
In 2009, Deputy Attorney General David Ogden released a memo
(“Ogden Memo”) discouraging federal prosecution of individuals using
marijuana for medical purposes in accordance with state law, reasoning
that such prosecutions would be a waste of federal resources.49 Although
the CSA entirely prohibits the cultivation and possession of marijuana, the
Ogden Memo stated that federal prosecutors should focus on illegal drug
trafficking networks rather than organizations acting in compliance with
state laws.50
In 2011, Deputy Attorney General James Cole reaffirmed the policy
stated in the Ogden Memo.51 Cole then directed prosecutors to take an
even more deferential stance to the states in 2013, issuing his own memo
(“Cole Memo”) guiding U.S. Attorneys by stating that the Department of
Justice (“DOJ”) would not prioritize enforcement of federal marijuana
laws in states with laws allowing use of marijuana, so long as the states
possess “strong and effective regulatory and enforcement systems.”52 The
Ogden Memo emphasized that state decriminalization could not prevent
federal enforcement of the CSA, sending contradictory messages of
restraint and readiness regarding state-sanctioned marijuana production.53
The Cole Memo guided federal prosecutors towards further reliance on
state regulation of medical marijuana, suggesting that federal prosecution
would be appropriate only where local authorities were not applying state

prosecutions in states authorizing the medical use of marijuana); see also
Memorandum from James M. Cole, Deputy U.S. Attorney General, to All U.S.
Attorneys (Aug. 29, 2013), http://www.justice.gov/iso/opa/resources/3052013829
132756857467.pdf [https://perma.cc/63SW-753T] [hereinafter “Cole 2013 Memo”]
(setting forth guidance regarding marijuana enforcement).
48. Supra note 47.
49. See Ogden Memo, supra note 47.
50. See id. (listing indicia such as unlawful use of firearms, violence, and
financial activities inconsistent with state law as signs that federal prosecutors
may want to investigate and prosecute a particular case involving marijuana).
51. Memorandum from James M. Cole, Deputy U.S. Attorney General, to
U.S. Attorneys (June 29, 2011), https://www.justice.gov/sites/default/files/oip
/legacy/2014/07/23/dag-guidance-2011-for-medical-marijuana-use.pdf [https://
perma.cc/94SF-N4SC].
52. See Cole 2013 Memo, supra note 47.
53. See Ogden Memo, supra note 47 (stating that prosecutors are not
precluded from investigating and prosecuting actions undertaken in compliance
with state law).
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regulations.54 The memoranda from Ogden and Cole suggested federal
prosecutors should not interfere with state marijuana decriminalization
and regulation, but maintained prosecutors’ power to enforce the CSA
regardless of state law.55
The policy of non-interference stated in the Ogden and Cole Memos
was not legislation, however, executive guidance documents are subject to
change. The early days of January 2018 brought such a change, as
Attorney General Jeff Sessions rescinded all previous guidance documents
regarding the enforcement of marijuana’s CSA prohibition.56 The actual
effects of this change remain unknown at this point, although the question
remains whether Attorney General Sessions’s memo rescinding the
Obama-era stance of noninterference will have any major impact in the
near future.57 Further, Sessions’s resignation from office adds further
uncertainty as any new Attorney General might make further changes to
DOJ policy. Although the rescission of the Ogden and Cole Memos pulls
back from a message of deference to state regulation, thereby giving
federal prosecutors more freedom to pursue violators of the CSA and
remain in line with the DOJ, it is unlikely that the government would target
organizations and individuals acting within state medical marijuana
guidelines because Attorney General Session’s memo did not explicitly
encourage such targeting of state-compliant organizations.58 Thus, while
the Ogden and Cole Memos are no longer guiding forces, the common
sense rationale behind them continues: namely, that DOJ funds are better
spent pursuing illicit drug trafficking connected to violence rather than
organized groups acting according to state regulations.
Sessions’s memo, still in effect unless and until the next Attorney
General rescinds it, supports the belief that the rescission of earlier
guidance documents will not greatly impact the prosecutorial discretion
that has been exercised regarding medical marijuana, as the memo
instructs federal prosecutors to follow the principles set forth in the U.S.

54. See Cole 2013 Memo, supra note 47.
55. See id.; see also Ogden Memo, supra note 47.
56. See Sessions Memo, supra note 46.
57. See Thomas Fuller, California Defiant in face of Federal Move to Get
Tough on Marijuana, N.Y. TIMES (Jan. 4, 2018), https://www.nytimes.com
/2018/01/04/us/california-defiant-in-face-of-federal-move-to-get-tough-on-mari
juana.html?mtrref=query.nytimes.com [https://perma.cc/XEB4-KEHL]; see also
The New York Times Editorial Board, Editorial, Jeff Session’s Endless War on
Marijuana, N.Y. TIMES (Jan. 7, 2018), https://www.nytimes.com/2018/01/07/
opinion/jeff-sessionss-war-marijuana.html [https://perma.cc/X3Q4-5L77].
58. See Sessions Memo, supra note 46.
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Attorneys’ Manual.59 Whether such a prosecution would be an effective
and efficient use of resources is among the principles the government uses
when determining whether to prosecute a case.60 How the DOJ will
proceed from this point, however, is not clear.
2. Congressional Budget Modifications
In addition to executive action, Congress has also taken steps to ensure
that federal agents respect state programs decriminalizing marijuana.61 In
2014, the government included a provision preventing the DOJ from using
funds to interfere with state medical marijuana programs in the
Congressional budget.62 Congress passed this provision every subsequent
year as well.63 The lack of funds available to federal prosecutors because
of this budgetary restriction has led to the dismissal of at least one case.64
The tension between the federal CSA and the state medical marijuana
decriminalization efforts persists.65 The legislative budgetary restrictions
remain in place as of now, since Congress included this provision in the
most recent spending bill in March 2018.66 The rescission of the Cole and
59. Id.
60. U.S. DEP’T OF JUST., U.S. ATTORNEYS’ MANUAL § 9:27.000 (Jan. 2017),
https://www.justice.gov/jm/jm-9-27000-principles-federal-prosecution
[https://perma.cc/VER3-C9YQ] (“[The principles] contribute to more effective
management of the government’s limited prosecutorial resources.”).
61. Consolidated and Further Continuing Appropriations Act, 2015, Pub. L.
No. 113-235, § 538, 128 Stat. 2130, 2217 (2014) (prohibiting the DOJ from
interfering with “[s]tate laws that authorize the use, distribution, possession, or
cultivation of medical marijuana”).
62. Id.
63. Joel Rubin, The feds seized guns, gold, and 320 pot plants. So why did a
judge rule they can’t pursue marijuana charges, L.A. TIMES (Aug. 14, 2017, 4:00
AM), http://www.latimes.com/local/california/la-me-medical-marijuana-court20170813-story.html [https://perma.cc/R37F-5LCR]; but see also Janet Burns,
Sessions to Congress: Please Forego Federal Law Protecting Medical Marijuana
States, FORBES (Jun. 13, 2017, 9:25 AM), https://www.forbes.com/sites/janetw
burns/2017/06/13/sessions-to-congress-please-forgo-federal-law-protecting-med
ical-marijuana-states/#29812e32727b [https://perma.cc/9VZP-QD32].
64. See Rubin, supra note 63.
65. See 42 U.S.C. § 12114 (2012); see also State Medical Marijuana Laws,
supra note 24.
66. Tom Angell, Congress Protects Medical Marijuana From Jeff Sessions
in New Federal Spending Bill, FORBES (Mar. 21, 2018, 8:02 PM), https://www
.forbes.com/sites/tomangell/2018/03/21/congress-protects-medical-marijuana-fromjeff-sessions-in-new-federal-spending-bill/#1082b6653575 [https://perma.cc/B959N78H].
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Ogden Memos seems to demonstrate the change in the DOJ’s perception
of state decriminalization, intensifying the uneasiness that defines the
coexistence of federal and state marijuana laws. Despite marijuana’s
federal illegality, analysis of preemption doctrine and state legislative
power demonstrates that states have the power to decriminalize the use of
medical marijuana, and further, the ability to provide valid employment
protections for state citizens wrongfully terminated because of marijuana
use.
II. THE CONFLICT OF FEDERAL AND STATE MARIJUANA LAW IN
EMPLOYMENT LAW
The simultaneous wholesale prohibition of marijuana under federal
law and decriminalization under state law creates significant conflict in all
areas of the law, including employment law. The illegality of marijuana
under the CSA prevents medical marijuana users from protection under
the ADA, the federal statute protecting individuals with disabilities from
discrimination.67 The ADA does not cover individuals engaged in the use
of illegal drugs, and marijuana’s status as a Schedule I substance under the
CSA places it within that exception.68
The ADA provides the most significant means of legal recourse
available to disabled individuals who encounter discrimination at work
because of their disabilities.69 If a person can perform the required tasks of
a job with a reasonable accommodation for his disability and that
reasonable accommodation does not cause undue hardship to the
employer, the ADA forbids discrimination against that person on the basis
of his disability.70 The statutes that comprise the ADA prohibit not only
discrimination based on a disability itself, but also forbids refusal to make
reasonable accommodations for the worker’s disability.71 This broad
proscription of discriminatory practices provides protection from
discrimination-based adverse employment actions for employees who

67. 42 U.S.C. § 12114.
68. Id.; see also Taylor Oyaas, Reefer Madness: How Tennessee Can Provide
Cannabis Oil Patients Protection from Workplace Discrimination, U. MEM. L.
REV. 935, 942–43 (2017) (describing the impossibility of employee protection for
use of medical marijuana under the ADA due to marijuana’s Schedule I status
under the CSA).
69. 42 U.S.C. § 12114; see also Oyaas, supra note 68.
70. 42 U.S.C. § 12112.
71. Id.
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have a disability, creating a cause of action for those whose disabilities
have not been reasonably accommodated.72
To make a prima facie case under the ADA, however, a claimant must
be a qualified individual, and the ADA specifically excludes employees
who use illegal substances under the CSA from the definition of a qualified
individual.73 Accordingly, the ADA is useless for employees who are
terminated based on their use of medical marijuana, since those individuals
are not qualified to sue under the statute.74
Any recourse available to such employees therefore, can only exist
within state law.75 Until recently, states’ attempts to provide employment
protection to medical marijuana users were routinely held to be invalid in
state courts. The primary rationales for these holdings were based on a
preemption theory or on statutory construction.76
A. The Lone Finding of Preemption: Emerald Steel
The United States Constitution states that federal law is the “supreme
Law of the Land.”77 If a federal law conflicts with a state law, the federal
law preempts the conflicting state law and renders it invalid.78 Whether the
CSA conflicts with and preempts state decriminalization laws is a central
and unanswered question.79 If the CSA preempts state statutes
decriminalizing medical marijuana, the state laws and protections they
provide would be without effect and prosecution for medical marijuana
use would be entirely at the whim of the federal government.80 The CSA’s
prohibition of marijuana as a Schedule I substance seems to stand in direct
conflict with state laws decriminalizing the drug, but the language of the

72. Id.
73. Id.
74. Id.
75. See Oyaas, supra note 68, at 935, 943.
76. See Coats v. Dish Network, L.L.C., 350 P.3d 849 (Colo. 2015) (holding that
the CSA’s prohibition on marijuana rendered it an unlawful activity outside of the
scope of state protections for employees prescribed medical marijuana); Emerald Steel
Fabricators, Inc. v. Bureau of Labor & Indus., 230 P.3d 518 (Or. 2010) (holding that
the CSA preempted Oregon’s Medical Marijuana Act which protected employees
against discrimination for their legal marijuana use outside of work).
77. U.S. CONST. art. VI, cl. 2.
78. Id.
79. See Chemerinsky et al., supra note 25, at 102–09.
80. See U.S. CONST. art. VI, cl. 2 (stating that laws of the United States made
in pursuance of the Constitution “shall be the supreme Law of the Land”); see
also Chemerinsky et al., supra note 25, at 74.
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CSA itself demonstrates no direct conflict exists when states decriminalize
marijuana.81
Four types of preemption exist: express; field; conflict; and obstacle.82
Express preemption only exists when Congress includes an explicit
provision in the federal statute stating an intention to preempt any state or
local laws.83 Field preemption is when the statute or statutory scheme
clearly states Congress intended to “occupy the field” and leave no room
for state or local legislatures to craft laws within that area.84 Neither of
these forms of preemption applies in the context of marijuana regulation.85
The CSA has no explicit preemption clause, demonstrating that express
preemption does not affect marijuana regulation.86
The CSA does, however, have an explicit provision that states that it
is not meant to “occupy the field” of drug legislation.87 That provision
instead says that the CSA does not preempt any state law unless “there is
a positive conflict” between the two, such that they cannot exist
simultaneously.88 This “positive conflict” language demonstrates that the
CSA can only overrule state law regarding decriminalization of marijuana
through the theories of either conflict or obstacle preemption.
Direct conflict preemption only occurs if it is impossible to obey both
federal and state laws at the same time.89 This standard is very narrow, and
one can meet it only when a state law requires an act contrary to a federal
law.90 Neither decriminalization of medical marijuana nor employment
protections for medical marijuana users under state law would conflict
with the CSA directly, since such provisions do not require possession,
use, or distribution of marijuana, but only allow it.91 Therefore, obstacle
preemption is the only type of preemption that could potentially apply.
81. 21 U.S.C. §§ 801, 903 (2012).
82. See Crosby v. Nat’l Foreign Trade Council, 530 U.S. 363, 372 (2000).
83. See Cipollone v. Liggett Group, Inc., 505 U.S. 504, 517 (1992).
84. See Crosby, 530 U.S. at 372 (quoting California v. ARC Am. Corp., 490
U.S. 93, 100 (1989)).
85. See 21 U.S.C. §§ 801–971 (demonstrating a lack of any express
preemption provision within the CSA); see also id. § 903 (explicitly stating that
the CSA is not meant to “occupy the field . . . to the exclusion of any State law on
the same subject matter”).
86. See id. §§ 801–971.
87. Id. § 903.
88. Id.
89. See Fla. Lime & Avocado Growers, Inc. v. Paul, 373 U.S. 132, 142–43 (1963).
90. See Chemerinsky et al., supra note 25, at 106.
91. See id.; see also LA. REV. STAT. § 40:966(I) (2018) (providing exemptions
for arrest and prosecution to persons lawfully in possession of medical marijuana,
but not requiring such possession).
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Obstacle preemption applies if the state law at issue is inconsistent with
the purposes and objectives of federal law.92
Only one court has found a state law regulating medical marijuana to
be preempted by the CSA using an obstacle preemption analysis.93 In
Emerald Steel Fabricators, Inc. v. Bureau of Labor & Industry, a
temporary employee used medical marijuana daily to treat his anxiety and
nausea, a permitted “debilitating medical condition” under the Oregon
Medical Marijuana Act.94 When the opportunity to become a permanent
employee arose, the employee informed his supervisor of his medical
marijuana use and provided his registry card to show that Oregon state law
sanctioned his use.95 The employer promptly terminated the employee, and
the employee filed a complaint for discrimination against the employer.96
The Supreme Court of Oregon found that the state law did not just
decriminalize the use of medical marijuana, but affirmatively authorized
its use.97 The state law therefore stood as an obstacle to the enforcement
of the CSA, such that the CSA preempted the state law.98
Emerald Steel is the only decision in which a state supreme court found
that the CSA preempts state laws providing protection for medical
marijuana users, and several contemporaries have criticized the decision.99
Obstacle preemption carries a strong presumption against preemption if the
federal law lies within an area the state traditionally governs.100 This
presumption against obstacle preemption should have led the Oregon
Supreme Court to find that the CSA did not preempt the state law protecting
medical marijuana users, as evidenced by other courts’ determinations that
obstacle preemption does not apply to state laws regulating medical
marijuana.101 The decision in Emerald Steel is an anomaly, and other courts
92. See Robert A. Mikos, Preemption Under the Controlled Substances Act,
16 J. HEALTH CARE L. & POL’Y 5, 23 (2013).
93. Emerald Steel Fabricators, Inc. v. Bureau of Labor & Indus., 230 P.3d
518 (Or. 2010).
94. Id. at 520; see also OR. REV. STAT. ANN. § 475B.415 (West).
95. Emerald Steel, 230 P.3d at 520.
96. Id.
97. Id.
98. Id. at 525.
99. See Oyaas, supra note 68, at 952–56; Elizabeth Rodd, Light, Smoke, and
Fire: How State Law Can Provide Medical Marijuana Users Protection from
Workplace Discrimination, 55 B.C. L. REV. 1759, 1782 (2014).
100. See Wyeth v. Levine, 555 U.S. 555, 565 (2009); see also Oyaas, supra
note 68, at 952–56; see also Chemerinsky et al., supra note 25, at 107–08.
101. White Mountain Health Ctr. Inc. v. Cty. of Maricopa, No. 2012-053585,
2012 WL 6656902, at *8 (Ariz. Super. Ct. Dec. 3, 2012) (applying an obstacle
preemption analysis to determine the CSA does not preempt Arizona’s Medical
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should find state laws that provide employment protection for medical
marijuana users valid and find that the CSA does not preempt them.102
B. The Significance of Statutory Language: Coats
Although preemption does not preclude states from protecting medical
marijuana users from employment discrimination, several cases have shown
that state courts may strike down ambiguous statutes providing medical
marijuana users protection.103 The tension between the CSA and state medical
marijuana statutes is the cause of the ambiguity problem; this tension renders
the word “lawful” ambiguous in state medical marijuana statutes.104 For
example, in Coats v. Dish Network, L.L.C., an employer terminated an
employee who used medical marijuana at home during nonworking hours.105
The employee sought a claim for wrongful termination, alleging that the
reason for his termination was his use of medical marijuana, a use in accord
with the state law of Colorado.106 Colorado’s wrongful termination statute
forbade employers from terminating employees for engaging in any “lawful
activity” outside of work.107
The employee in Coats argued that the word “lawful” in the context
of the statute meant lawful in accordance with Colorado state law.108 The
Colorado Supreme Court determined instead that “lawful” meant an
activity that complies with both state and federal law.109 Because
marijuana use remains illegal under federal law, the Colorado Supreme
Court found that employees’ wrongful termination protection could not
extend to individuals using medical marijuana.110 An employee could only
have a claim for wrongful termination if the activity for which he was

Marijuana Act); Kirby v. Cty. of Fresno, 195 Cal. Rptr. 3d 815, 831–32 (Ct. App.
2015) (holding that the CSA did not preempt California’s statutory limitation on
marijuana arrests under the Compassionate Use Act and Medical Marijuana
Program Act).
102. See Oyaas, supra note 68, at 952–56, see also Chemerinsky et al., supra
note 25, at 107–08; see also Rodd, supra note 99, at 1782; see also Brilmayer,
supra note 25, at 895.
103. See, e.g., Coats v. Dish Network, L.L.C., 350 P.3d 849 (Colo. 2015); Ross
v. RagingWire Telecomms., Inc., 174 P.3d 200, 202–03 (Cal. 2008).
104. Coats, 350 P.3d at 849.
105. Id.
106. Id.
107. COLO. REV. STAT. § 24-34-402.5(1) (2012).
108. Coats, 350 P.3d at 850.
109. Id. at 852 (quoting People v. Schuett, 833 P.2d 44, 47 (Colo. 1992)).
110. Id. at 849.
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terminated was lawful under both state and federal law.111 Statutory
construction of the word “lawful” created a bar for employees seeking
protection under Colorado statutes for their medical marijuana use.112
Coats and similar jurisprudence show that the tension between federal and
state law regarding marijuana regulation requires precise statutory
language in order to survive judicial scrutiny and successfully provide
employment protections for medical marijuana users.
Prior to 2017, no court found a claim enforceable for employer
discrimination based on an employee’s use of state-sanctioned medical
marijuana.113 In the summer of 2017, however, two state court decisions
allowed claims for wrongful termination and discrimination to proceed.114
These two cases, Barbuto v. Advantage Sales and Noffsinger v. SSC Niantic
Operating Company, L.L.C., upheld two different types of statutory
protection for medical marijuana users, demonstrating viable paths for
protecting medical marijuana users from employment discrimination.115 The
first of these cases, Barbuto, found that the Massachusetts medical marijuana
laws did not themselves create a cause of action for discrimination, but did
provide a claim under a state handicap discrimination law.116
C. The Use of Broad Protection of Rights as a Bridge: Barbuto
In July of 2017, the Massachusetts Supreme Court became the first
state supreme court to find that a claim for employment discrimination
based on an individual’s state-sanctioned use of medical marijuana could
move forward.117 The statute at issue stated “[a]ny person [qualifying for
use of medical marijuana] shall not be penalized under Massachusetts law
111. Id.
112. Id.
113. See, e.g., id.; Emerald Steel Fabricators, Inc. v. Bureau of Labor & Indus.,
230 P.3d 518 (Or. 2010); Ross v. RagingWire Telecomms., Inc., 174 P.3d 200,
202–03 (Cal. 2008).
114. See Barbuto v. Advantage Sale & Mktg., LLC, 78 N.E.3d 37 (Mass.
2017) (holding that, while the Massachusetts Medical Marijuana Act did not
create its own private cause of action, that statute’s language forbidding
“penaliz[ation] under Massachusetts law . . . or deni[al] [of] any right or privilege”
for qualified use of medical marijuana did support a claim for handicap
discrimination under Massachusetts law); see also Noffsinger v. SSC Niantic
Operating Co., 273 F. Supp. 3d 326 (D. Conn. 2017) (holding that Connecticut’s
Palliative Use of Marijuana Act created an implied private right of action through
its anti-discrimination employment provision).
115. See Barbuto, 78 N.E.3d at 37; see also Noffsinger, 2017 WL 3401260.
116. See Barbuto, 78 N.E.3d at 37.
117. Id.
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in any manner, or denied any right or privilege, for such actions.”118 In
Barbuto v. Advantage Sales, the Massachusetts Supreme Court found this
broad provision of the Massachusetts Medical Marijuana Act to allow an
individual to maintain a claim of handicap discrimination under another
state statute.119 The Court refused to find that marijuana’s illegality under
the CSA made its medical use a per se unreasonable accommodation under
the state handicap statute.120
The Massachusetts Supreme Court did not find that the medical
marijuana statutes themselves created a private cause of action.121 Instead,
a state anti-handicap discrimination law preserved the plaintiff’s claim.122
The medical marijuana statute, by not hinging employment discrimination
on the legality of the substance, avoided any possible ambiguity that might
derail the purpose of the law.123 The Massachusetts Legislature crafted a
statute that protected medical marijuana users from civil penalty, creating
state-level protections that would not be invalidated because of the CSA’s
prohibition of marijuana. Although the medical marijuana statute was
insufficient on its own to create a cause of action for the affected
employee, it served as a bridge to other anti-discrimination statutes.124
Unlike the Massachusetts statute, the Connecticut federal district court
found the Connecticut provision at issue in Noffsinger to create its own
cause of action and serve as an independent vehicle for anti-discrimination
protections.125

118. MASS. GEN. LAWS ANN. ch. 151B, § 4(16) (2018).
119. See 2012 MASS. ACTS 369 (declaring that “[a] qualifying patient . . . shall
not be subject to civil penalty, for the medical use of marijuana”); see also MASS.
GEN. LAWS ANN. ch. 151B, § 4(16) (forbidding an employer to discriminate
against an employee based on their handicap).
120. Barbuto, 78 N.E.3d at 46 (stating “[t]o declare an accommodation for
medical marijuana to be per se unreasonable out of respect for Federal law would
not be respectful of the recognition of Massachusetts voters . . . that marijuana has
an accepted medical use”).
121. Barbuto, 78 N.E.3d 37.
122. Id. at 47–48.
123. 2012 MASS. ACTS 369.
124. Barbuto, 78 N.E.3d at 47–48.
125. Noffsinger v. SSC Niantic Operating Co., 273 F. Supp. 3d 326 (D. Conn.
2017) (holding that Conn. Gen. Stat. § 21a-408p(b) created a private cause of
action for employees to sue under for discrimination by employers based on their
use of medical marijuana).
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D. The Creation of Private Rights of Action: Noffsinger
In contrast to Barbuto, the United States District Court for the District
of Connecticut found that a specific anti-discrimination provision included
in the Connecticut Palliative Use of Marijuana Act provided a private
cause of action for employees terminated for the use of medical
marijuana.126 The statute says in pertinent part, “No employer may refuse
to hire a person or may discharge, penalize or threaten an employee solely
on the basis of such person’s or employee’s status as a qualifying
patient.”127 The district court found that the CSA did not preempt the
provision, since no tension between the two laws rose to the level of
conflict required for obstacle preemption.128 The CSA does not explicitly
prohibit employers from hiring applicants that may be using illegal
substances, meaning that the Connecticut statute was no obstacle to the
CSA and therefore was not preempted.129 Additionally, the federal court
found that the provision of Connecticut law did not authorize use of illegal
substances in the workplace, preventing ADA preemption.130
Coming fast on the heels of Barbuto, Noffsinger was another case in
which a federal court recognized that states were able to protect employees
using medical marijuana without the CSA preempting protection.131 Further,
the statute in Noffsinger did not need another statute to function as an
employment protection.132 The Connecticut Legislature had successfully
written a law that filled the gap in employment protection the ADA’s
exclusion of CSA Schedule I substances caused, and created a means of
suing an employer for discriminatory actions based on an employee’s
legitimate use of medical marijuana.133 The Connecticut federal court
determined that the inclusion of a specific anti-discrimination provision
created an implied private cause of action under the medical marijuana
statute itself.134 Louisiana, unlike Massachusetts and Connecticut, has no
statute that could serve as a means of protecting citizens that use medical

126. Id.
127. CONN. GEN. STAT. § 21a-408p(b) (2018).
128. Id.
129. Id.
130. Id.
131. Id.
132. Noffsinger v. SSC Niantic Operating Co., 273 F. Supp. 3d 326 (D. Conn.
2017) (holding that Conn. Gen. Stat. § 21a-408p(b) created a private cause of
action for employees to sue under for discrimination by employers based on their
use of medical marijuana).
133. CONN. GEN. STAT. § 21a-408p(b).
134. Id.
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marijuana. This is a gap in the law that the Louisiana Legislature must fill
to allow citizens access to the healthcare they need.135
III. LOUISIANA’S INCOMPLETE MEDICAL MARIJUANA STATUTES
Louisiana’s program for medical marijuana access exists through two
statutes: Louisiana Revised Statutes § 40:966, which exempts participants
in the medical marijuana program from criminal prosecution; and Louisiana
Revised Statutes § 40:1046, which establishes the means of production,
recommendation, and distribution of medical marijuana for citizens with a
qualifying debilitating disease.136 Unlike Massachusetts’s medical
marijuana statutes, Louisiana’s two statutes do not include a provision
ensuring that any qualified user of medical marijuana “shall not be penalized
under [Louisiana] law in any manner, or denied any right or privilege, for
[such use of medical marijuana].”137 The Louisiana statutes also do not
provide an explicit employment anti-discrimination provision like the one
in Connecticut’s medical marijuana statute.138
The two statutes that comprise Louisiana’s medical marijuana
program lack any form of protection for employees eligible to use medical
marijuana.139 Without modification, an individual suffering from one of
the debilitating diseases that qualifies her for medical marijuana use will
have a serious decision to make. She can seek effective medication for his
illness by fulfilling a recommendation for medical marijuana, but in so
doing risk losing her job. Alternatively, she can continue to suffer in order
to maintain gainful employment. To protect Louisiana citizens from being
forced to choose between their health and their livelihood, the Louisiana
Legislature must modify the current medical marijuana statutes to include
an anti-discrimination provision.
IV. FINDING A WAY THROUGH THE WEEDS
If the United States Congress would recognize the medical uses of
marijuana and reschedule it under the CSA, Louisiana’s government
would not need to act. Federal anti-discrimination protections under the
ADA would become available to employees whose doctors recommend

135.
136.
137.
138.
139.

See LA. REV. STAT. §§ 40:966, 40:1046 (2018).
Id.
MASS. GEN. LAWS ANN. ch. 94C App., §§ 1–4 (West) (2018).
See CONN. GEN. STAT. § 21a-408p(b).
LA. REV. STAT. §§ 40:966(I), 40:1046A(2)(a).
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medical marijuana, rendering the need for state law protections moot.140
Such Congressional action seems unlikely considering the current political
climate and lack of bipartisan cooperation.141 The response to former
Attorney General Jeff Session’s rescission of the Ogden and Cole memos
may signify changing times, especially because 33 states have legalized
marijuana.142 Barring a surprising Congressional effort to amend the CSA,
the onus falls on Louisiana to craft legislation creating statutory protections
for employees using medical marijuana.
A. Louisiana Should Adopt an Explicit Employment Anti-Discrimination
Provision
With the CSA as it currently stands, only state law can protect
employees who suffer debilitating conditions that entitle them to use
medical marijuana under Louisiana law. To fill the current gap in its medical
marijuana statutes, Louisiana should look to states with employment
protections for medical marijuana users that have survived judicial scrutiny.
Barbuto and Noffsinger evidence that the CSA will not necessarily
preempt medical marijuana statutes designed to protect employees from
wrongful termination and discrimination based on their marijuana use.143
In Barbuto, the Massachusetts Supreme Court found that a Massachusetts
provision forbidding the imposition of civil penalties because of a citizen’s
medical marijuana use could act as a bridge to other anti-discrimination
statutes.144 The court invoked a state handicap law to effectuate
employment protection, marking the Massachusetts statutory scheme as

140. See 42 U.S.C. § 12114 (2012). If the federal government rescheduled
marijuana under the CSA it would no longer be an illegal drug, allowing users of
medical marijuana to fall within the definition of qualified disabled employee under
the ADA. Additionally, Louisiana doctors would be able to accurately term their
actions as “prescribing” marijuana rather than “recommending” it. See supra note 3.
141. See Jennifer Steinhauer, With Few Wins in Congress Republicans Agree
on Need to Agree, N.Y. TIMES (Aug. 4, 2017), https://www.nytimes.com/2017/08
/04/us/politics/congress-republican-agree-unity.html [https://perma.cc/TD38-G3
W9]; see also The New York Times Editorial Board, Editorial, Canada, but Not
Jeff Sessions, Moves Boldly on Marijuana, N.Y. TIMES (Apr. 15, 2017), https://
www.nytimes.com/2017/04/15/opinion/sunday/canada-but-not-jeff-sessions-move
s-boldly-on-marijuana.html [https://perma.cc/M7HB-F2RN].
142. See The New York Times Editorial Board, supra note 57 (noting the
negative responses of Republican and Democrat leaders on Capitol Hill).
143. See Barbuto v. Advantage Sale & Mktg., LLC, 78 N.E.3d 37 (2017);
Noffsinger v. SSC Niantic Operating Co. LLC, 273 F. Supp. 3d 326 (D. Conn. 2017).
144. Barbuto, 78 N.E.3d 37.
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functional, but not ideal.145 In contrast, Connecticut’s Palliative Use of
Marijuana Act includes an express employment anti-discrimination
provision, creating a private cause of action for employees who have been
victims of discrimination.146 A similarly explicit anti-discrimination
provision is the best solution to fill Louisiana’s current gap in medical
marijuana legislation, as it would create a clear and unambiguous means
of suing for employment discrimination under state law.
B. A Model Statutory Provision that Balances Employee and Employer
Needs
The model provision below is based on Connecticut law and
incorporates protection from discrimination into Louisiana Revised
Statutes § 40:1046. It uses the definitions already found in the Louisiana
medical marijuana statutes to create a clear and unambiguous protection
from employment discrimination on the basis of medical marijuana use:147
No employer may refuse to hire a person or may discharge,
penalize, or threaten an employee solely on the basis of such
person’s or employee’s status as a patient suffering from a
debilitating medical condition as defined in §1046(A)(2)(a) and
recommended medical marijuana as defined in §1046(A)(3).
Nothing in this subdivision shall restrict an employer’s ability to
prohibit the use of intoxicating substances during work hours or
restrict an employer’s ability to discipline an employee for being
under the influence of intoxicating substances during work hours.
An explicit employment anti-discrimination provision, such as the one
above, will eliminate any federal law interference, creating a means of suing
for discrimination beyond any claims of CSA preemption.148 Although the
broad protection of the Massachusetts Medical Marijuana Act also resulted
in a possible solution to the lack of employment protection for medical
marijuana users, it did not create a cause of action within the medical
marijuana statutes, but instead created a right to sue under the state’s antihandicap discrimination statutes.149 A broad statement that citizens’ rights
145. See MASS. GEN. LAWS ANN. ch. 151B, § 4(16) (2018); 2012 MASS. ACTS
369 (2018).
146. See CONN. GEN. STAT. § 21a-408p(b) (2018).
147. LA. REV. STAT. § 40:1046 (2018).
148. See Noffsinger, 273 F. Supp. 3d 326.
149. See Barbuto, 78 N.E.3d at 41.
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will not be abridged because of medical marijuana use could create a
loophole for employers to argue that the ADA applies and renders any
attempted protection null because of marijuana’s illegality under the CSA,
thereby making it an ineffective solution to the problem in Louisiana law.150
Louisiana should therefore include an anti-discrimination provision, similar
to that of Connecticut, in Louisiana’s medical marijuana statutes. Such a
provision will create an unambiguous means of employment protection that
will exist wholly within state law and that the CSA will not affect. Such a
provision might also face some opposition from employers around the state,
who fear a parade of impaired workers that they are prevented from
replacing with more conscientious staff.
Louisiana employers might oppose such an anti-discrimination provision
in the belief that it would allow workers to come to work incapacitated. If
Louisiana were to adopt the Connecticut medical marijuana anti-discrimination
provision as its model, however, these fears would be unfounded.151 The
protections granted to employees would not force employers to accept
lackluster or unprofessional work behavior from individuals.152 Employees
would not be allowed to abuse the protected use of medical marijuana; instead,
the state would strike a balance between necessary protections for employees
and freedom to conduct business for employers.153
CONCLUSION
Louisiana’s provisions governing the regulation of medical marijuana
have yet to go into effect, but the state is steadily progressing towards the
implementation of a statutory medical marijuana program. 154 Although
150. See Coats v. Dish Network, L.L.C., 350 P.3d 849 (Colo. 2015).
151. CONN. GEN. STAT. § 21a-408p(b)(3) (stating that employers will still have
the right to punish or terminate employees who use medical marijuana while at
work and on the clock).
152. Id.
153. The explicit anti-discrimination provision would function in the same
way as a claim under the ADA, and this provision would not be a guarantee of
employment. Instead, it would be held to the same standard as a claim under the
ADA, with an emphasis on the reasonableness of the employee’s behavior and the
employer’s reasons for termination.
154. See LA. REV. STAT. § 40:966(I) (2018); id. § 40:1046A(2)(a). See also
Mark Ballard, LSU Board moves forward on medical marijuana contract; CEO:
‘We are not a pot company’, ADVOCATE (June 22, 2017, 12:05 PM), https://
www.theadvocate.com/baton_rouge/news/education/article_063b2546-576d-11e
7-b089-c76fc00501d6.html [https://perma.cc/3WA7-UWH5]; see also Ted
Griggs, Ready, set, grow: Southern University picks medical marijuana business
vendor, ADVOCATE (Sept. 22, 2017, 1:15 PM), https://www.theadvocate.com/
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gaps in the statutory scheme currently exist, the Louisiana Legislature can
fill these holes and protect employees with debilitating medical conditions
from discrimination.155 Marijuana is entirely illicit under federal law, but an
anti-discrimination provision modeled off of the version in the Connecticut
Palliative Use of Marijuana Act would achieve the goal of protecting
employees from discrimination and avoiding federal preemption.156
The provision would create a private state law cause of action under
which employees could sue for protection against discrimination.157 The
provision would simultaneously preserve the right of employers to
discipline workers who come to the workplace intoxicated, no matter their
status as medical marijuana patients.158 Earlier employee attempts to seek
protection from employment discrimination under state medical marijuana
decriminalization laws have failed because of either statutory construction
or preemption. The federal court’s upholding of the Connecticut provision,
however, demonstrates its viability as a means of protecting those workers
who would otherwise have to choose between their health and their jobs.159
The Louisiana Legislature has taken a huge step forward by legalizing
medical marijuana, and it is a step that will improve the lives of suffering
citizens. But the Legislature must now look forward and fill the remaining
gaps in citizen protections before the medical marijuana program is fully
implemented, in order to give the most complete benefit to Louisiana’s
citizens. Louisiana should learn from its sister states and draft legislation
to protect individuals who use medical marijuana for relief from symptoms
of chronic illnesses. Citizens should not have to weigh their health and
well-being against their hopes of gainful employment.
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159. See, e.g., Coats v. Dish Network, L.L.C., 350 P.3d 849 (Colo. 2015);
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